SSA
CERE

Schonfeld Strategic Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-42,575
Closed -$1.74M – 2552
2024
Q2 		$1.74M Buy
42,575
+40,905
+2,449% +$1.7M 0.01% 962
2024
Q1 		$70.6K Buy
1,670
+1,153
+223% +$48.4K ﹤0.01% 1878
2023
Q4 		$21.9K Buy
+517
New +$14.9K ﹤0.01% 1697
2023
Q3 		– Sell
-66,390
Closed -$2.11M – 2437
2023
Q2 		$2.11M Buy
+66,390
New +$2.04M 0.02% 735
2023
Q1 		– Sell
-15,400
Closed -$486K – 2794
2022
Q4 		$486K Buy
+15,400
New +$435K ﹤0.01% 1539
2022
Q1 		– Sell
-8,546
Closed -$277K – 3002
2021
Q4 		$277K Buy
+8,546
New +$302K ﹤0.01% 1546
2021
Q2 		– Sell
-13,002
Closed -$178K – 2402
2021
Q1 		$178K Buy
+13,002
New +$190K ﹤0.01% 1548

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Schonfeld Strategic Advisors's CERE Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 42,575 shares — an estimated $1.74M sold.

Schonfeld Strategic Advisors first reported a position in CERE in Q1 2021 and held it in 7 quarters. The position peaked at $2.11M in Q2 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 42,575 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.74M.
  • Schonfeld Strategic Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.11M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.